CN1129431C - 苯并芳庚并吡啶类化合物与抗肿瘤药联合用于治疗增生性疾病 - Google Patents

苯并芳庚并吡啶类化合物与抗肿瘤药联合用于治疗增生性疾病 Download PDF

Info

Publication number
CN1129431C
CN1129431C CN98813742A CN98813742A CN1129431C CN 1129431 C CN1129431 C CN 1129431C CN 98813742 A CN98813742 A CN 98813742A CN 98813742 A CN98813742 A CN 98813742A CN 1129431 C CN1129431 C CN 1129431C
Authority
CN
China
Prior art keywords
alkyl
substituted
aryl
purposes
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN98813742A
Other languages
English (en)
Chinese (zh)
Other versions
CN1284875A (zh
Inventor
W·R·比肖普
J·J·卡蒂诺
R·J·多尔
A·甘古利
V·吉里雅瓦拉布汉
P·基尔施梅尔
M·刘
L·L·尼尔森
D·L·库特勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27385940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1129431(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1284875A publication Critical patent/CN1284875A/zh
Application granted granted Critical
Publication of CN1129431C publication Critical patent/CN1129431C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN98813742A 1997-12-22 1998-12-21 苯并芳庚并吡啶类化合物与抗肿瘤药联合用于治疗增生性疾病 Expired - Fee Related CN1129431C (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US99602797A 1997-12-22 1997-12-22
US08/996,027 1997-12-22
US08/996027 1997-12-22
US14352998A 1998-08-28 1998-08-28
US09/143,529 1998-08-28
US09/143529 1998-08-28
US18196998A 1998-10-29 1998-10-29
US09/181,969 1998-10-29
US09/181969 1998-10-29

Publications (2)

Publication Number Publication Date
CN1284875A CN1284875A (zh) 2001-02-21
CN1129431C true CN1129431C (zh) 2003-12-03

Family

ID=27385940

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98813742A Expired - Fee Related CN1129431C (zh) 1997-12-22 1998-12-21 苯并芳庚并吡啶类化合物与抗肿瘤药联合用于治疗增生性疾病

Country Status (25)

Country Link
EP (1) EP1041985B1 (enExample)
JP (1) JP4502503B2 (enExample)
KR (1) KR100700907B1 (enExample)
CN (1) CN1129431C (enExample)
AR (1) AR017440A1 (enExample)
AT (1) ATE317697T1 (enExample)
AU (1) AU756762B2 (enExample)
BR (1) BR9814419A (enExample)
CA (1) CA2315693C (enExample)
CL (1) CL2007001889A1 (enExample)
CO (1) CO5080764A1 (enExample)
CZ (1) CZ298511B6 (enExample)
DE (1) DE69833509T2 (enExample)
DK (1) DK1041985T3 (enExample)
ES (1) ES2255196T3 (enExample)
HU (1) HUP0102473A3 (enExample)
IL (1) IL136462A0 (enExample)
MY (1) MY137303A (enExample)
NO (1) NO326832B1 (enExample)
NZ (1) NZ504928A (enExample)
PE (1) PE20000042A1 (enExample)
PT (1) PT1041985E (enExample)
SK (1) SK285584B6 (enExample)
TW (1) TW581763B (enExample)
WO (1) WO1999032114A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
DE60016625T2 (de) * 1999-11-09 2005-12-22 Societe De Conseils De Recherches Et D'applications Scientifiques(S.C.R.A.S.) Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterotrimerischen g-proteinen in kombination mit einem anderen anti-krebs-mittel zu einer therapeutischen verwendung in der krebsbehandlung
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
US20030186925A1 (en) * 2000-02-29 2003-10-02 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
EP1261348A2 (en) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
WO2001064197A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
WO2001064226A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
WO2001064196A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
EP1267871A2 (en) * 2000-02-29 2003-01-02 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US6645966B2 (en) * 2001-01-22 2003-11-11 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
JP4969016B2 (ja) * 2001-02-15 2012-07-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物
HUP0402401A2 (hu) * 2001-11-30 2005-03-29 Schering Corp. Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával
EP1453513A1 (en) * 2001-12-03 2004-09-08 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
CN105198758A (zh) * 2015-09-22 2015-12-30 湖南大学 一种高纯度(z)-他莫昔酚的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
AU665341B2 (en) * 1990-12-18 1996-01-04 Wellcome Foundation Limited, The Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
JP2767176B2 (ja) * 1992-12-15 1998-06-18 大塚製薬株式会社 抗癌剤
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
DE69635114T2 (de) * 1995-08-09 2006-03-02 Banyu Pharmaceutical Co., Ltd. Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids
TW350844B (en) * 1995-12-22 1999-01-21 Schering Corp Tricyclic amides useful to inhibition of G-protein function and for treatment of proliferative diseases
EP0932399B1 (en) * 1996-03-12 2006-01-04 PG-TXL Company, L.P. Water soluble paclitaxel prodrugs
JP2000507584A (ja) * 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
US20020034725A1 (en) * 1996-04-15 2002-03-21 W. Gillies Mckenna Sensitization of cells to radiation and and chemotherapy
CA2251955A1 (en) * 1996-04-18 1997-10-23 Nancy E. Kohl A method of treating cancer
JP2000508335A (ja) * 1996-05-30 2000-07-04 メルク エンド カンパニー インコーポレーテッド 癌の治療方法
US6337992B1 (en) * 1997-01-29 2002-01-08 Philips Medical Systems Technologies Ltd. Predictive bolus tracking
CA2282683A1 (en) * 1997-02-18 1998-08-20 Canji, Inc. Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms

Also Published As

Publication number Publication date
CL2007001889A1 (es) 2008-01-11
EP1041985A1 (en) 2000-10-11
DE69833509T2 (de) 2006-10-26
AU756762B2 (en) 2003-01-23
CN1284875A (zh) 2001-02-21
PT1041985E (pt) 2006-07-31
SK8982000A3 (en) 2001-04-09
NO326832B1 (no) 2009-02-23
JP2001526224A (ja) 2001-12-18
AR017440A1 (es) 2001-09-05
NZ504928A (en) 2004-12-24
HUP0102473A3 (en) 2003-07-28
BR9814419A (pt) 2000-10-10
CA2315693A1 (en) 1999-07-01
CZ20002236A3 (cs) 2001-04-11
ATE317697T1 (de) 2006-03-15
WO1999032114A1 (en) 1999-07-01
IL136462A0 (en) 2001-06-14
KR100700907B1 (ko) 2007-03-29
ES2255196T3 (es) 2006-06-16
CZ298511B6 (cs) 2007-10-24
TW581763B (en) 2004-04-01
HUP0102473A2 (hu) 2002-01-28
CO5080764A1 (es) 2001-09-25
NO20003229L (no) 2000-08-22
DE69833509D1 (de) 2006-04-20
AU1907299A (en) 1999-07-12
CA2315693C (en) 2010-11-30
EP1041985B1 (en) 2006-02-15
PE20000042A1 (es) 2000-02-17
DK1041985T3 (da) 2006-06-19
KR20010033452A (ko) 2001-04-25
MY137303A (en) 2009-01-30
JP4502503B2 (ja) 2010-07-14
NO20003229D0 (no) 2000-06-21
SK285584B6 (sk) 2007-04-05

Similar Documents

Publication Publication Date Title
CN1129431C (zh) 苯并芳庚并吡啶类化合物与抗肿瘤药联合用于治疗增生性疾病
CN1419452A (zh) 协同治疗癌症的方法和组合物
CN1049891C (zh) 双环胺类化合物及其制备方法和含该化合物的药物组合物
US6096757A (en) Method for treating proliferative diseases
CN1546472A (zh) 吡啶基链烷烃-和吡啶基链炔径-酸酰胺作为细胞抑制剂和免疫抑制剂
CN1195740C (zh) 含2－喹啉酮的药物组合物
CN1496256A (zh) 用于治疗增生性疾病的埃博霉素(epo thilone)类似物和化疗剂的组合
CN1203590A (zh) 具有抗癌和细胞活素抑制活性的取代咪唑类化合物
CN101039673A (zh) 用于治疗涉及细胞增殖的疾病的组合
CN1290165A (zh) 苯并噻唑蛋白酪氨酸激酶抑制剂
CN1253150C (zh) 单独的或与抗血小板聚集药物联合的Xa因子抑制剂
CN1138773C (zh) 4-链烯基(和炔基)氧吲哚作为细胞周期蛋白-依赖性激酶尤其是cdk2的抑制剂
CN1364084A (zh) 诱导癌细胞死亡和肿瘤消退的方法
CN1219174A (zh) 蛋白质法呢基转移酶的抑制剂
CN1711089A (zh) 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合给药
CN1568322A (zh) 作为蛋白jun激酶抑制剂的有亲油和可离子化部分的药学活性磺酰胺衍生物
CN1473043A (zh) 一种利用取代的吡唑治疗变态反应的方法
CN1318058A (zh) 用作cetp抑制剂的4－羧基氨基－2－取代的－1,2,3,4－四氢喹啉
CN1853723A (zh) 采用MDM2：p53相互作用的小分子抑制剂的联合治疗
HK1041260A1 (zh) 2-脲基噻唑衍生物及其製備方法和作為抗腫瘤劑的應用
CN1791410A (zh) 通过抑制jnk治疗或预防炎性或代谢性病症的方法
CN1910183A (zh) 四氢咔啉化合物作为抗癌药
CN1921885A (zh) Sr蛋白质的磷酸化控制方法以及以sr蛋白质活性控制剂为有效成分的抗病毒剂
CN1993347A (zh) 钾通道抑制剂
CN1882342A (zh) Chk1抑制剂在控制细胞增殖中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20031203

Termination date: 20101221